Affinity Asset Advisors LLC Buys 130,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Affinity Asset Advisors LLC increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 185.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,000 shares of the biotechnology company’s stock after purchasing an additional 130,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $12,540,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of ARWR. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. First Horizon Corp bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $32,000. WPG Advisers LLC increased its holdings in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 431 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $54,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ARWR shares. Piper Sandler reissued an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday. Weiss Ratings cut Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Sanford C. Bernstein boosted their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective for the company. Finally, Chardan Capital boosted their price objective on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.83.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $85.60 on Friday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a market capitalization of $12.06 billion, a PE ratio of -39.81 and a beta of 1.26. The stock’s 50 day moving average price is $77.94 and its 200-day moving average price is $69.97. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $15.01 and a 52-week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter in the previous year, the company earned $2.75 earnings per share. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.08 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.